A Study on the Efficacy and Safety of Benzonatate Soft Capsules for Improving Adult Cough Symptoms
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03722914 |
Recruitment Status : Unknown
Verified March 2018 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..
Recruitment status was: Recruiting
First Posted : October 29, 2018
Last Update Posted : October 29, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cough | Drug: Benzonatate 200 mg Drug: blank control 0mg | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 220 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Multicentric Randomized Double-blind Placebo-controlled Study on the Efficacy and Safety of Benzonatate Soft Capsules for Improving Adult Cough Symptoms |
Actual Study Start Date : | March 1, 2018 |
Estimated Primary Completion Date : | December 31, 2018 |
Estimated Study Completion Date : | July 31, 2019 |
Arm | Intervention/treatment |
---|---|
Active Comparator: benzonatate soft capsules group |
Drug: Benzonatate 200 mg
200 mg/pellet, 1pellet/time, 3times/day |
Placebo Comparator: control group |
Drug: blank control 0mg
0 mg/pellet, 1pellet/time, 3times/day |
- reducion of cough symptoms total scores [ Time Frame: 7days ]The reduction of cough symptoms will be evaluated by comparative score index basal and final score
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age between 18 and 75 years of age;
- the onset time is more than 3 days and less than 8 weeks;
- dry cough, the total score of cough symptom in day and night is greater than 4;
- Willing to sign informed consent.
Exclusion Criteria:
- allergic person or known to the test drug containing ingredients (including benzo, soybean oil, glycerin, gelatin) allergy;
- the cough symptoms are caused by bronchial asthma, tuberculosis, pneumoconiosis, bronchiectasis, tumor and other diseases that have been clearly diagnosed.
- coughers caused by drugs;
- respiratory depression or airway obstruction;
- patients with uncontrolled diabetes or hypertension;
- having difficulty in swallowing or affecting drug absorption, such as active peptic ulcer and acute gastritis;
- patients with severe hematopoietic system, nervous system, mental illness (including alcohol and substance abuse) or immunodeficiency diseases;
- laboratory examination results are abnormal with clinical significance, among which: A.C r is higher than normal value; B.A LT and/or AST>2 times normal value upper limit (ULN).
- women during pregnancy or lactation or women who are preparing for pregnancy or lactation during the trial;
- in the first 3 months of screening, any other experimental drug treatment was accepted;
- Failure to comply with test plans or other conditions that other researchers believe is not appropriate for the group.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03722914
Contact: Lou Kun, Master | 0311-67808817 | loukun@mail.ecspc.com |
China, Beijing | |
Beijing hospital | Recruiting |
Beijing, Beijing, China, 100000 | |
Contact: Guo Yanfei, Master | |
Beijing luhe hospital affiliated to capital medical university | Recruiting |
Beijing, Beijing, China, 100000 | |
Contact: Xu Zhenyang, Master | |
Beijing pinggu district hospital | Recruiting |
Beijing, Beijing, China, 100000 | |
Contact: Jin Xiuhong, Master | |
Peking University People's Hospital | Recruiting |
Beijing, Beijing, China, 100000 | |
Contact: Cao Zhaolong, M.D. | |
China, Heilongjiang | |
Second affiliated hospital of Harbin medical university | Recruiting |
Harbin, Heilongjiang, China, 150000 | |
Contact: Chen Hong, Master | |
China, Henan | |
Zhengzhou first people's hospital | Recruiting |
Zhengzhou, Henan, China, 450000 | |
Contact: Chang Shuangxi, Master | |
China, Hunan | |
Second Hospital of Xiangya | Recruiting |
Changsha, Hunan, China, 410000 | |
Contact: Chen Ping, M.D. | |
China, Inner Mongolia | |
Affiliated hospital of Inner Mongolia medical university | Recruiting |
Hohhot, Inner Mongolia, China, 010000 | |
Contact: Wang Lihong, Master | |
Inner Mongolia autonomous region people's hospital | Recruiting |
Hohhot, Inner Mongolia, China, 010000 | |
Contact: Yun Chunmei, Master | |
China, Jilin | |
First hospital of jilin university | Recruiting |
Changchun, Jilin, China, 130000 | |
Contact: Peng Liping, M.D. | |
Jilin Province People's Hospital | Recruiting |
Changchun, Jilin, China, 130000 | |
Contact: Li Hui, M.D. | |
China, Liaoning | |
Affiliated Zhongshan Hospital Dalian University | Recruiting |
Dalian, Liaoning, China, 116000 | |
Contact: Pei Fuyang, Master | |
First Affiliated Hospital of China Medical University | Recruiting |
Shenyang, Liaoning, China, 110000 | |
Contact: Kang Jian, M.D. | |
China, Shanghai | |
Central hospital of yangpu district, Shanghai | Recruiting |
Shanghai, Shanghai, China, 200000 | |
Contact: Xu Xiaowen, Master |
Principal Investigator: | Cao Zhaolong, M.D. | Peking University People's Hospital |
Responsible Party: | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT03722914 |
Other Study ID Numbers: |
EY20170501 |
First Posted: | October 29, 2018 Key Record Dates |
Last Update Posted: | October 29, 2018 |
Last Verified: | March 2018 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Cough Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory |
Benzonatate Antitussive Agents Respiratory System Agents |